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Abstract.  Invasive  mold  infection  (IMI)  remains  a  major  cause  of  mortality  in  high
hematological  patients.  The  aim  of  this  multicenter  retrospective,  observational  study  was  to 
evaluate antifungal combination  therapy (ACT)  for proven  and probable IMI in hematological 
patients. We analyzed 61 consecutive cases of proven (n=25) and pr
ACT  collected  from  eight  Spanish  hospitals  from  January  2005  to  December  2009.  Causal 
pathogens were: Aspergillus spp (n=49), 
spp  (n=3).  Patients  were  classified  in  thre
employed: Group A, liposomal amphotericin B (L
AmB  plus  a  triazole  (n=20),  and  Group  C,  voriconazole  plus  a  candin  (n=21).  ACT  was  well 
tolerated with minimal adverse effects. Thirty
(35  complete).  End  of  treatment  and  12
without  statistical  differences  among  groups.  Granulocyte  recovery  was  significantly  related  to 
favorable  response  and  survival  (p<0.001)  in  multivariate  analysis.  Our  results  suggest  that 
comparable outcomes can be achieved with ACT in high risk hematological patients with proven or 
probable IMI, whatever the combination of antifungal agents used. 
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Invasive  mold  infection  (IMI)  remains  a  major  cause  of  mortality  in  high
hematological  patients.  The  aim  of  this  multicenter  retrospective,  observational  study  was  to 
evaluate antifungal  combination therapy (ACT) for  proven and  probable  IMI  in hematological 
patients. We analyzed 61 consecutive cases of proven (n=25) and probable (n=36) IMI treated with 
ACT  collected  from  eight  Spanish  hospitals  from  January  2005  to  December  2009.  Causal 
spp (n=49), Zygomycetes (n=6), Fusarium spp (n=3), and 
spp  (n=3).  Patients  were  classified  in  three  groups  according  to  the  antifungal  combination 
employed: Group A, liposomal amphotericin B (L-AmB) plus caspofungin (n=20); Group B, L
AmB  plus  a  triazole  (n=20),  and  Group  C,  voriconazole  plus  a  candin  (n=21).  ACT  was  well 
effects. Thirty-eight patients (62%) achieved a favorable response 
(35  complete).  End  of  treatment  and  12-week  survival  rates  were  62%  and  57%  respectively, 
without  statistical  differences  among  groups.  Granulocyte  recovery  was  significantly  related  to 
vorable  response  and  survival  (p<0.001)  in  multivariate  analysis.  Our  results  suggest  that 
comparable outcomes can be achieved with ACT in high risk hematological patients with proven or 
probable IMI, whatever the combination of antifungal agents used.  
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Invasive  mold  infection  (IMI)  remains  a  major  cause  of  mortality  in  high-risk 
hematological  patients.  The  aim  of  this  multicenter  retrospective,  observational  study  was  to 
evaluate antifungal combination therapy (ACT) for proven  and probable  IMI in  hematological 
obable (n=36) IMI treated with 
ACT  collected  from  eight  Spanish  hospitals  from  January  2005  to  December  2009.  Causal 
spp (n=3), and Scedosporium 
e  groups  according  to  the  antifungal  combination 
AmB) plus caspofungin (n=20); Group B, L-
AmB  plus  a  triazole  (n=20),  and  Group  C,  voriconazole  plus  a  candin  (n=21).  ACT  was  well 
eight patients (62%) achieved a favorable response 
week  survival  rates  were  62%  and  57%  respectively, 
without  statistical  differences  among  groups.  Granulocyte  recovery  was  significantly  related  to 
vorable  response  and  survival  (p<0.001)  in  multivariate  analysis.  Our  results  suggest  that 
comparable outcomes can be achieved with ACT in high risk hematological patients with proven or Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
Introduction.  Severe  neutropenia  and 
immunosuppression  resulting  from  the  use  of  high-
dose chemotherapy in hematological diseases followed, 
in  selected  cases,  by  allogeneic  stem  cell 
transplantation  (allo-SCT),  increase  the  susceptibility 
of  patients  to  invasive  fungal  disease  (IFD).  The 
growing use of these aggressive therapies has led to a 
remarkable  increase  in  the  incidence  of  IFD.
1-3 
Although  fluconazole  prophylaxis  has  reduced  yeast 
infections  in  these  vulnerable  populations,  invasive 
mold  infections  (IMI),  particularly  those  caused  by 
Aspergillus spp, have steadily increased to a 10-20% 
incidence rate. Furthermore, a high mortality rate for 
aspergillosis,  the  most  common  IMI,  has  been 
described, especially among allo-SCT recipients.
1-5 In 
addition, zygomycosis can reach attributable mortality 
rates of 91% in these patients.
6 
Many  attempts  have  been  made  to  decrease  the 
incidence  and  mortality  of  IFD  in  patients  with 
hematological  malignancies.  Strategies  including 
empiric  therapy,
7-9  pre-emptive  treatment
10-13  and 
improved prophylactic regimens with new azoles have 
been proposed.
14-19 Monotherapy with new antifungal 
agents  such  as  candins,  triazoles  and  liposomal 
amphotericin  B  (L-AmB)  has  also  been  used  as 
treatment  for  proven  or  probable  IFD.
20-23  However, 
though improved survival rates have been documented 
with  the  use  of  these  individual  agents,  overall 
response and treatment outcome remain suboptimal in 
cases of IMI with high mortality rates.  
Recently,  several  retrospective  or  uncontrolled 
clinical reports
24-30 and, as far as we know, only one 
prospective  randomized  study
31  have  addressed  the 
potential  benefit  of  using  combinations  of  new 
antifungal agents in the treatment of IFD. This issue is 
conceptually promising, because an additive activity or 
even synergy of antifungal drugs might be expected.
32 
Although these studies provide evidence supporting the 
use  of  this  approach,  the  advantages  of  combined 
therapy  have  not  yet  been  clearly  demonstrated.
25-32 
Therefore,  it  is  still  unclear  if  antifungal  combined 
therapy (ACT) is superior to monotherapy in severely 
neutropenic and/or immunocompromised patients with 
life-threatening IFD.  
In  this  retrospective,  observational,  multicenter 
study, we describe the results of ACT in 61 proven or 
probable  cases  of  IMI  occurring  in  high-risk 
hematological  patients  treated  with  intensive 
chemotherapy or allo-SCT.  
 
Patients  and  Methods.  We  have  retrospectively 
analyzed  all  consecutive  cases  of  high-risk 
hematological  patients  with  proven  or  probable  IMI 
treated with ACT in eight tertiary university hospitals 
in  Spain  over  a  5-year  period  (January  2005  - 
December 2009). For inclusion in the analysis, patients 
must  have  received  at  least  seven  days  of  ACT. 
Antifungal agents used as primary prophylaxis, empiric 
treatments or in ACT depended on the specific policies 
of participating hospitals.  
 
Definitions.  Diagnosis  of  IMI  was  established 
according  to  the  revised  EORTC/MSG  criteria.
33 
Responses  to  antifungal  therapy  were  defined 
according to the MSG/EORTC consensus criteria
34 as 
either  favorable  response  (complete  or  partial)  or 
failure (stable disease, progression or death from any 
cause). 
Prophylaxis was defined as primary when patients 
did not have a previous history of IFD, while it was 
defined as secondary in patients with a previous IFD 
history but no signs or symptoms of fungal infection 
when the new hematological treatment was initiated.  
ACT was started when the diagnosis of proven or 
probable  IFD  was  made.  The  following  doses  were 
used in the treatment of adult patients: voriconazole, 
loading dose of 6 mg/kg/12 hours x 2 doses followed 
by 4 mg/kg/12 hours; posaconazole, 400 mg/12 hours; 
caspofungin, 70 mg on day 1 and 50 mg/day starting 
from day 2; anidulafungin, 200 mg on day 1 and 100 
mg/day after and L-AmB, 3 mg/kg/day. The doses used 
in  the  treatment  of  children  were:  voriconazole,  7 
mg/kg/12 hours; caspofungin, 70 mg/m
2 (maximum 70 
mg) on the first day and 50 mg/m
2 (maximum 50 mg) 
each  subsequent  day  and  L-AmB,  3  mg/kg/day.  All 
drugs were given intravenously but posaconazole was 
administered  orally.  Azole  plasma  levels  were  not 
monitored. 
De novo ACT was defined as the combination of 
two antifungal drugs not used before for prophylaxis or 
empiric treatment. Sequential ACT occurred when an 
antifungal  drug  was  added  to  another  already  being 
used for prophylaxis or empiric treatment.  
 
Statistical  Analysis.  Data  were  collected  in  a  SPSS 
database  and  all  statistical  results  were  performed 
using  SPSS  version  17.  Either  the  chi-square  or  the 
Fisher’s exact test were used to compare data. Overall 
survival  was  analyzed  using  temporal  series  Kaplan-
Meier  analysis  and  comparisons  between  different 
treatments groups were performed using the log-rank 
test. For multivariate analysis, logistic regression was 
used.  A  p  value  of  less  than  0.05  was  defined  as 
statistically significant. 
 
Results. 
Patients. Sixty-one patients were included in the study. 
The  mean  age  was  43  years  (range,  3-73)  with  7 
patients younger than 18 years. Thirty-four patients had 
received intensive chemotherapy for induction (n=28)  
 Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
Table 1. Patient characteristics 
Characteristics  All patients 
n (%)=61 (100) 
Group A 
n (%)=20 (33) 
Group B 
n (%)=20 (33) 
Group C 
n (%)=21 (34) 
Age mean (range)  43 (3-73)  44 (8-64)  48 (21-73)  39 (3-72) 
Sex (M/F)  34 (56)/27 (44)  11 (55)/ 9 (45)  14 (70) / 6 (30)  9 (43)/12 (57) 
Underlying disease       
   
AML  27 (44)  11 (55)  7 (35)  9 (43) 
ALL  19 (31)  3 (15)  9 (45)  7 (33) 
SAA  2 (3)  1 (5)  1 (5)  0 
MDS  8 (13)  3 (15)  2 (10)  3 (14) 
NHL  3 (5)  1 (5)  1 (5)  1 (5) 
MM  1 (2)  1 (5)  0  0 
BPL  1 (2)  0  0  1 (5) 
Allo-SCT  25 (41)  8 (40)  8 (40)  9 (43) 
HLA-identical sibling   10 (16)  2 (10)  2 (10)  6 (29) 
Adult unrelated donor  4 (6)  1 (5)  2 (10)  1 (5) 
Cord blood  11 (18)  5 (25)  4 (20)  2 (10) 
High risk condition         
SN  45 (74)  17 (85)  13 (65)  15 (71) 
Acute GvHD + SN  9 (15)  1 (5)  3 (15)  5 (24) 
Acute GvHD  3 (5)  1 (5)  2 (10)  0 
Chronic GvHD  3 (5)  1 (5)  1 (5)  1 (5) 
Severe IS  1 (2)  0  1 (5)  0 
Acute GvHD         
Grade 0  13 (21)  6 (30)  3 (15)  4 (19) 
Grade I-II  9 (15)  2 (10)  3 (15)  4 (19) 
Grade III-IV  3 (5)  0  2 (10)  1 (5) 
IFD diagnosis (EORTC/MSG)         
Proven   25 (41)  8 (40)  10 (50)  7 (33) 
Probable  36 (59)  12 (60)  10 (50)  14 (67) 
Sites of Infection         
Pulmonary  51 (84)  19 (95)  13 (65)  19 (90) 
Disseminated  8 (13)  1 (5)  5 (25)  2 (10) 
Paranasal sinuses  2 (3)  0  2 (10)  0 
Fungal Pathogen         
Aspergillus spp  49 (67)  18 (90)  14 (70)  17 (81) 
Zygomycetes  6 (10)  0  3 (15)  3 (14) 
Scedosporium spp  3 (5)  1 (5)  1 (5)  1 (5) 
Fusarium spp  3 (5)  1 (5)  2 (10)  0 
M: male, F: female, HLA: human leukocyte antigen. AML: acute myeloid leukemia. ALL: acute lymphoblastic leukemia. SAA: severe 
aplastic anemia. MDS: myelodysplastic syndrome. NHL: non-Hodgkin lymphoma. MM: multiple myeloma. BPL: byphenotypic leukemia. 
SN:  severe  neutropenia.  GvHD:  Graft  versus  Host  Disease.  Group  A:  L-amB  plus  caspofungin.  Group  B:  L-amB  plus  triazole  (16 
voriconazole and 4 posaconazole). Group C: Voriconazole plus candin (20 caspofungin and 1 anidulafungin) 
 
or  consolidation  (n=6).  Twenty-five  patients  were 
recipients  of  allo-SCT  and  one  patient  received  an 
autologous SCT. The main  demographic  and clinical 
data are shown in Table 1. 
Fifty-four patients (89%) were severely neutropenic 
(absolute  neutrophil  count  <500/µL  for  at  least  10 
consecutive days) at the onset of IFD; of these, 9 had at 
the same time acute graft versus host disease (GvHD). 
Only  7  patients  developed  an  IFD  without  severe 
neutropenia:  3  patients  had  acute  GvHD,  3  patients 
chronic  GvHD  and  1  patient  severe  aplastic  anemia 
under immunosuppressive treatment.  
Prior antifungal prophylaxis was administered to 60 
patients  (23  voriconazole,  18  fluconazole,  18 
itraconazole and 1 L-AmB). In 35 patients, prophylaxis 
was stopped when empirical antifungal treatment was 
initiated  (9  patients  were  given  voriconazole,  16 
caspofungin and 10 L-AmB). The patient not receiving 
prophylaxis  started  empirical  treatment  with 
voriconazole.  Only 3 patients with prior history of IFD 
(2  candidemias  and  1  probable  pulmonary 
aspergillosis)  received  secondary  prophylaxis  (1 
fluconazole, 2 voriconazole). 
De novo ACT was started in 26 patients. In 23 other 
patients, combined treatment was initiated by adding a 
new antifungal agent to the empirical treatment. In the 
remaining  12  patients,  a  second  antifungal  drug  was 
added to the prophylaxis regimen. 
The diagnosis of proven IFD was confirmed in 25 
patients,  while  the  remaining  36  patients  met  the 
criteria for probable IFD. The molds isolated in proven 
IFD  cases  were  as  follows:  Aspergillus  fumigatus 
(n=6),  A.  flavus  (n=3),  A.  terreus  (n=1),  Aspergillus 
spp.  (n=3),  Mucor  spp.  (n=6),  Fusarium  oxysporum Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
Table  2.  Therapeutic  results  of  different  ACT  regimens  in  the 
global series (n=61) 
  Group A 
n=20 
n (%) 
Group B 
n=20 
n (%) 
Group C 
n=21 
n (%) 
Response 
    Favorable 
     Complete 
     Partial 
    Failure 
Death related to IFD 
Alive  at  the  end  of 
treatment 
Alive at 12 weeks 
 
13 (65) 
11 (55) 
2 (10) 
7 (35) 
6 (30) 
 
13 (65) 
11 (55) 
 
12 (60) 
11 (55) 
1 (5) 
8 (40) 
8 (40) 
 
12 (60) 
11 (55) 
 
13 (62) 
13 (62) 
0 (0) 
8 (38) 
8 (38) 
 
13 (62) 
13 (62) 
IFD  indicates  invasive  fungal  disease.  Group  A:  L-amB  plus 
caspofungin. Group B: L-amB plus triazole (16 voriconazole and 4 
posaconazole).  Group  C:  Voriconazole  plus  candin  (20 
caspofungin, 1 anidulafungin). 
 
(n=1),  Fusarium  spp.  (n=2),  Scedosporium 
apiospermum (n=2) and S. prolificans (n=1). All cases 
of probable IFD were aspergillosis. All patients with 
mucormycosis  were  treated  with  ACT  and  surgery, 
with  the  exception  of  one  patient  with  pulmonary 
mucormycosis diagnosed at postmortem examination. 
Antifungal Combination Therapy. The mean duration 
of ACT was 31 days (range, 8-127). Three antifungal 
combination groups were identified: group A, L-AmB 
plus caspofungin (20 patients); group B, L-AmB plus 
triazole  (voriconazole  16  and  posaconazole  4)  and 
group C, voriconazole plus candin (20 caspofungin and 
1 anidulafungin). 
Toxicity.  ACT  was  well  tolerated  except  for  a  mild 
increase  in  liver  enzymes  in  patients  receiving 
voriconazole and a mild increase in serum creatinine 
levels in two patients receiving L-AmB. In one case, L-
AmB  treatment  was  discontinued  for  two  days 
returning  the  serum  creatinine  level  to  normal 
following a dose reduction from 3 to 1.5 mg/kg/day for 
two  additional  days.  Hypokalemia  was  observed  in 
patients receiving L-AmB, but they responded well to 
potassium supplements. 
Outcome.  Thirty-eight  patients  had  a  favorable 
response to ACT  [35  complete response  (CR) and  3 
partial responses (PR)]. The survival rate at the end of 
treatment  was  62%  for the  whole series  and  the 12-
week survival rate after initiation of ACT was 57%. 
In  group  A,  13  (65%)  patients  had  favorable 
response (11 CR, 2 PR), in group B, 12 (60%) patients 
(11  CR,  1  PR  response)  and  in  group  C,  13  (62%) 
patients (13 CR). We found no statistical differences in 
terms of clinically favorable responses among groups 
A, B and C (Table 2). 
Survival rates at the end of treatment for groups A, 
B and C were 65%, 60% and 62%, respectively. The 
probability of survival at 12 weeks for groups A, B, 
and C were 55%, 55% and 62%, respectively (Figure 
1A).  We  found  no  significant  differences  in  the 
Table 3. Therapeutic results of different ACT regimens in patients 
diagnosed with proven or probable invasive aspergillosis (n=49) 
 
Group A 
n=18 
n (%) 
Group B 
n=14 
n (%) 
Group C 
n=17 
n (%) 
Response 
    Favorable 
           Complete 
           Partial 
    Failure 
Death related to IFD 
Alive  at  the  end  of 
treatment 
Alive at 12 weeks 
 
13 (72) 
11 (61) 
2 (11) 
5 (28) 
5 (28) 
 
13 (72) 
11 (61) 
 
8 (57) 
8 (57) 
0 (0) 
6 (43) 
5 (36) 
 
8 (57) 
8 (57) 
 
11 (65) 
11 (65) 
0 (0) 
6 (35)  
6 (35) 
 
11 (65) 
11 (65) 
IFD  indicates  invasive  fungal  disease.  Group  A:  L-amB  plus 
caspofungin. Group B: L-amB plus triazole (12 voriconazole and 2 
posaconazole).  Group  C:  Voriconazole  plus  candin  (16 
caspofungin, 1 anidulafungin) 
 
probability  of  survival  at  12  weeks  between  patients 
treated with de novo ACT compared with those treated 
with  sequential  ACT  through  addition  of  another 
antifungal  agent  to  previous  prophylaxis  or  empiric 
therapy (Figure 1B). 
A  total  of  20  out  of  27  patients  (74%)  receiving 
induction  or  consolidation  chemotherapy  for  AML 
achieved  a  favorable  response  to  ACT  while  a 
favorable  response  occurred  in  only  14  out  of  25 
recipients  of  allo-SCT  (56%).  Survival  at  12  weeks 
was  higher  in  AML  (64%)  compared  to  allo-SCT 
(52%). However these differences were not statistically 
significant. 
  Twenty-three patients died. Deaths were related to 
IFD  alone  (n=8),  IFD  in  the  setting  of  progressive 
underlying  disease  (n=14),  and  cytomegalovirus 
infection plus acute GvHD (n=1). From the end of the 
combined treatment to 12 weeks after the initiation of 
ACT, 3 additional patients died due to chronic GvHD 
(n=1)  and  leukemia  relapse  (n=2).  IFD-related 
mortality at 12 weeks was 39%.  
Antifungal  Combination  Therapy  in  Aspergillosis. 
Invasive  aspergillosis  (IA)  was  diagnosed  in  49 
patients  (13  proven  and  36  probable).  A  total  of  32 
(65%)  patients  responded  favorably  to  treatment  (30 
CR and 2 PR), and the end of treatment and 12-week 
survival rates were 65% and 61%, respectively. 
In group A, 13 of 18 patients (72%) responded (11 
CR and 2 PR), in group B, 8 of 14 patients (57%, 8 
CR) and in group C, 11 of 17 patients (65%, 11 CR). 
We  found  no  statistical  difference  between  response 
rates  among  groups  A,  B  and  C  (Table  3). 
Furthermore,  there  were  no  significant  differences in 
survival  at  12  weeks  among  groups  A,  B  and  C 
(Figure 2A). Moreover, no significant differences were 
observed between patients treated with de novo ACT 
and  those  with  sequential  ACT  (Figure  2B).  The 
probability of death at 12 weeks attributable to IA was 
found to be 34%. Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
 
Figure 1. A. Kaplan-Meier curves comparing the overall survival at 12 weeks related to different ACT in the global series: Group A: L-AmB 
+ candin (   ), Group B: L-AmB + triazole (-----) and Group C: triazole + candin (-·-·-·-). B. Kaplan-Meier curves comparing the overall 
survival at 12 weeks related to different antifungal combinations: “de novo” ACT (-----) and ACT as the result of adding an antifungal drug 
to a treatment already being used for prophylaxis or empiric treatment (   ) in the global series. 
Figure 2. A. Kaplan-Meier curves comparing the overall survival at 12 weeks with respect to different ACT in patients with IA: Group A: L-
AmB + candin (), Group B: L-AmB + triazole (-----) and Group C: triazole + candins (-·-·-·-). B. Kaplan-Meier curves comparing the 
overall survival at 12 weeks with respect to different antifungal combinations: “de novo” ACT (-----) and ACT as the result of adding an 
antifungal drug to the used for prophylaxis or empiric treatment () in patients diagnosed of IA . 
 
Analysis  of  Prognostic  Factors.  Univariate  analysis 
revealed that the use of non-active mold prophylaxis 
(fluconazole or no prophylaxis) influenced unfavorably 
the  ACT  response  (p=0.03)  and  mortality  (p=0.03), 
while granulocyte recovery and complete remission of 
the  underlying  malignancy  improved  the  response  to 
ACT  (p<0.001  and  p=0.009,  respectively)  and 
decreased  mortality  (p<0.001  and  p=0.002 
respectively). Other clinical variables such as age, stem 
cell transplantation, de novo ACT and IA did not show 
significant influence on response or mortality. Logistic 
regression  multivariate  analysis  revealed  that 
granulocytic  recovery  was  the  only  statistically 
significant variable (p<0.001) (Table 4). 
 When  we  analyzed  these  variables  separately  in 
groups  A,  B  and  C  only  granulocyte  recovery  was 
statistically  significant  for  response  (p=0.004  and 
p=0.02 for group A and B, respectively) and survival at 
12  weeks  (p=0.02  and  p=0.007  for  group  A  and  B, 
respectively).  In  group  C  all  patients  with  no 
granulocyte recovery died. 
 
Discussion. This study shows that ACT seems to be 
suitable  for  the  treatment  of  IFD  in  severely 
immunocompromised  patients.
20-23  Our  results  are  in 
line  with  those  previously  reported.
24-31  It  should  be 
noted  that  the  three  types  of  ACT  employed  in  our 
patients resulted in similar response rates in both the 
overall series and in patients with IA. These findings 
do  not  support  the  results  that  in  both  in  vitro  and 
animal  models  have  been  reported.
35,36  These  studies 
have suggested an antagonism with the combination of 
L-AmB  and  voriconazole.  Probably,  as  Segal  & 
Steinbach
37  have  stated,  a  major  limitation  in  the 
antifungal field is the lack of consistent ability to use in 
vitro models to predict clinical efficacy. In general,  
Table 4. Univariate analysis of factors influencing response to ACT and 12-week overall survival  Mediterr J Hematol Infect Dis 2012; 4: Open Journal System   
 
 
Variable                                                     n (%) 
Response 
    n (%)                 p value 
Survival at 12 weeks 
    n (%)                p value 
 
Age (adults/children)                                       54 (89) / 7 (12) 
 
Stem cell transplantation (yes/no)                  26 (43) / 35 (57) 
 
Non-active mold prophylaxis (yes/no)           19 (31) / 42 (69) 
 
ACT “de novo” (yes/no)                                  26 (43) / 35 (57) 
 
Granulocytic recovery* (yes/no)                    35 (57) / 26 (43) 
 
Aspergillosis IFD (yes/no)                               49 (80) / 12 (20) 
  
Complete remission status (yes/no)               44 (72) / 17 (28)     
 
 
35 (65) / 3 (43)            0.3 
 
15 (58) / 23 (66)          0.5 
 
  8 (42) / 30 (71)          0.03 
 
15 (58) / 23 (66)          0.5 
 
  33 (94) / 5 (19)         <0.001 
 
32 (65) / 6 (50)            0.3 
 
  32 (73) / 6 (35)           0.009 
 
32 (59) / 3 (43)           0.4 
 
14 (54) / 21 (60)         0.6 
 
    7 (37) / 28 (67)        0.033 
 
14 (54) / 21 (60)         0.6 
 
  31 (89) / 4 (15)        <0.001 
 
30 (61) / 5 (42)           0.2 
 
 31 (71) / 4 (24)          0.002 
ACT indicates antifungal combination therapy. IFD: invasive fungal disease. 
*Only granulocyte recovery was significantly associated to an improved response and survival in multivariate analysis (p<0.001). 
 
antagonism  has  not  been  apparent  in  the  clinical 
setting.  In  fact,  a  recent  study  by  Cornely  et  al
38 
suggested that prior azole prophylaxis or therapy did 
not  affect  overall  response  nor  mortality  in  patients 
who were treated with L-AmB for IMI (49% response 
rate  in  patients  given  previously  azoles  vs.  46%  in 
those  without  prior  azole  exposure).  Survival  at  12 
weeks was also similar (64% vs. 66%). 
Although  our  study  is  not  a  prospectively 
randomized  trial,  we  believe  it  provides  valuable 
information  on  the  potential  impact  of  ACT  in 
seriously  ill  patients  with  hematological  diseases.  In 
fact,  as  far  as  we  know,  the  only  prospective 
randomized trial reported is a pilot study by Caillot et 
al.
31  which  included  a  small  number  of  patients  (15 
patients  in  each  arm).  High  dose  L-AmB  (10 
mg⁄kg⁄day)  was  compared  with  a  combination  of 
standard dose L-AmB (3 mg/kg⁄day) plus caspofungin 
in  30  patients  with  hematologic  malignancies  and 
proven  or  probable  invasive  aspergillosis 
(COMBISTRAT  trial).  Response  rates  at  the  end  of 
treatment were 67% for the combination vs. 27% with 
monotherapy  (p=  0.03).  Survival  rates  at  12  weeks 
were similar, 100% for the combination and 80% for 
monotherapy.  Nevertheless,  this  study  indicated  the 
superiority of standard L-AmB plus caspofungin over 
high-dose L-AmB monotherapy, which in addition had 
a higher toxicity. On the other hand, the consistently 
better results in most retrospective case studies using 
ACT in the treatment of probable and proven IFD are 
similar to those obtained in the present study.
24-31 
An increasing number of patients with IFD and life-
threatening  conditions can  be cured  with ACT  when 
the  underlying disease  is  under  control. It should be 
noted  that,  in  our  case  series,  as  in  other  published 
reports,
39  ACT  was  well  tolerated  with  only  minor 
toxicity. In contrast, some case series in which single 
drugs  were  used  had  similar  or  higher  toxicity  than 
those  reported  in  the  present  study.
20,22  However, 
retrospective studies usually suffer from potential bias. 
For instance, in our study only patients who survived at 
least 7 days from the start of ACT were considered for 
analysis,  and consequently, patients with very severe 
infections  may  have  been  excluded  from  the  study. 
This  criticism  may  be  applied  to  most  clinical  trials 
that  exclude  patients  with  poor  performance  status 
(ECOG  ≥2),  life-expectancy  less  than  one  week  or 
severe organ dysfunction. 
Regarding prognostic factors, granulocyte recovery 
resulting from the control of the underlying disease is 
the most important variable in IFD patients regardless 
of  the  ACT  used.  The  use  of  ACT  instead  of 
monotherapy  may  more  efficiently stabilize the IFD, 
preventing  fatal  progression  while  neutrophil  counts 
recover  and  the  immune  system  is  restored.  This 
finding  raises  again  the  question  about  the  potential 
utility  of  granulocyte  transfusions  as  adjunctive 
treatment.  After  years  of  controversy,  the  RING 
(Resolving  Infections  in  Neutropenia  with 
Granulocytes) study has been designed to evaluate the 
effectiveness  of  transfusing  large  numbers  of  G-
CSF/dexamethasone  mobilized  granulocytes  from 
community donors. When available, the results of this 
multicenter  phase  III  randomized  controlled  clinical 
trial may be of  great value to definitely address this 
unresolved issue.
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